Comparison of RAEB-T with AML
| . | RAEB-T median (range) . | AML . | P . |
|---|---|---|---|
| Caspase 3 activity* | 7.87 (0-26) | 1.94 (0-26) | .0001 |
| PCNA* | 3.35 (.98-7.88) | 1.92 (.74-17.28) | .008 |
| Age | 61.5 (19-84) | 59.5 (16-87) | NS |
| AHD | 1 (0-1000) | 0 (0-168) | .0001 |
| B2M | 2.4 (1-8.10) | 2.6 (0-31) | NS |
| PLT | 38.5 (1-471) | 49 (3-2292) | .017 |
| HGB | 7.7 (3.6-15.1) | 7.8 (2.8-15) | NS |
| VEGF* | 4 (1-15) | 3 (5-15) | .04 |
| BM cellularity | 65 (5-100) | 75 (5-100) | .05 |
| Poor cytogenetics (−5,−7,11q23,+8) | 50% | 35% | .001 |
| Therapy-related | 27% | 15% | .011 |
| . | RAEB-T median (range) . | AML . | P . |
|---|---|---|---|
| Caspase 3 activity* | 7.87 (0-26) | 1.94 (0-26) | .0001 |
| PCNA* | 3.35 (.98-7.88) | 1.92 (.74-17.28) | .008 |
| Age | 61.5 (19-84) | 59.5 (16-87) | NS |
| AHD | 1 (0-1000) | 0 (0-168) | .0001 |
| B2M | 2.4 (1-8.10) | 2.6 (0-31) | NS |
| PLT | 38.5 (1-471) | 49 (3-2292) | .017 |
| HGB | 7.7 (3.6-15.1) | 7.8 (2.8-15) | NS |
| VEGF* | 4 (1-15) | 3 (5-15) | .04 |
| BM cellularity | 65 (5-100) | 75 (5-100) | .05 |
| Poor cytogenetics (−5,−7,11q23,+8) | 50% | 35% | .001 |
| Therapy-related | 27% | 15% | .011 |
The values of caspase 3 activity, PCNA, and VEGF represent folds of the mean level observed in 12 normal control bone marrows, which is assigned a value of 1.